medigraphic.com
ISSN 1561-3186 (Electronic)

2020, Number 4

<< Back Next >>

Rev Acta Médica 2020; 21 (4)

Cardiovascular Risk Factor in patients with Adrenal Incidentaloma

Domínguez PN, Martínez COC, Nuez VM

Language: Spanish
References: 30
Page: 1-13
PDF size: 457.25 Kb.


ABSTRACT

Introduction: High frequency of cardiovascular risk factors has been reported in patients with adrenal incidentaloma. Its direct relationship has also been demonstrated in patients with adrenal incidentaloma and subclinical hypercortisolism.
Objectives: To describe cardiovascular risk factors in patients with adrenal incidentaloma and to determine its association with the presence of subclinical hypercortisolism.
Methods: A retrospective descriptive study was carried out in patients with adrenal incidentaloma diagnosed by computerized axial tomography between January 2006 and November 2018.
Results: The sample included one hundred patients. The most frequent cardiovascular risk factors were overweight/obesity (68%), dyslipidemia (64%), and arterial hypertension (62%). Overweight/obesity (80%) and arterial hypertension (80%) were significantly more frequent in patients with benign adenoma. Dyslipidemia was also more frequent (73.3%), but without significant differences. Subclinical hypercortisolism occurred in seventeen patients, the majority in the benign adenoma group. A significant relationship was demonstrated between subclinical hypercortisolism, arterial hypertension and diabetes/prediabetes. The absence of subclinical hypercortisolism had a significant relationship with the absence of cardiovascular risk factors.
Conclusions: Cardiovascular risk factors were frequent in patients with adrenal incidentaloma. Most of these cases showed a significant association with subclinical hypercortisolism.


REFERENCES

  1. Velez H, Rojas W, Borrero J. Incidentalomas adrenales. Endocrinología 7ma. ed. CIB editores; Medellín Colombia. 2012:283-84

  2. Young W. The incidentally discovered adrenal mass. N Eng J Med 2007;356:601-10

  3. Gisbert P, Rivas D, Salomon S. Incidentaloma adrenal: Revisión. Rev Med Uni 2016;12(1). Disponible en: https://bdigital.uncu.edu.ar/7717

  4. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A et al. A Survey on Adrenal Incidentaloma in Italy. J Clin Endocrinol Metab. 2010; 85:637-44

  5. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2015;96:2004-15

  6. Fassnacht M, Aret W, Bancos I, Dralle H, Newell J, Sahdev A, et al. Managment of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline. Eur J Endocrinol. 2016;175(2):1-34

  7. Martínez O, Pereira I. Adrenal incidentaloma: a study of 65 patients. Endocrine Reviews 2014; Endocrine Society’s 96th Annual Meeting and Expo: SAT-0799: DOI: http://press.endocrine.org/doi/10.1210/endo-meetings.2014.AHPAA.9.SAT-0799#sthash.no9CNMn0.dpuf

  8. Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentaloma in Japan: the first report of clinical and epidemilogical features. Endo J. 2019;18-0486. DOI: http//doi:10.1507/endocrj. EJ18-0486

  9. Ioannis I, Kollias G, Gouli K, Dimitrios A. Patients with apparently nonfunctioning adrenal incidentalomas may be increased Cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab 2014;9(8):45-97

  10. Tuna M, Nasrolug N, Aycicek B, Becker D. Non- functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. J Endocrinol Invest. 2014;13(8):765-68

  11. Terzolo M, Adrenal Incidentaloma: A New Cause of the Metabolic Syndrome? J Clin Endocrinol Metab, 2002;87(3):998-1003

  12. Peppa M, Boutati E, Koliac C. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: A cause effect relationship? Metabolism. 2010;59:1435-41

  13. Di Dalmazi G, Vicennati V, Rinaldi E, Morselli – Labate A, Giamplama E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross- sectional study. Eur J Endocrinol. 2012;166:669-77

  14. Morelli V, Reimondo G, Giordano R. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab. 2014;99(3):827-34

  15. Toniato A, Merante-Boschin I, Opocher G, Pelizzo M, Schiavi F, Ballotta E, et al. Surgical versus conservative management for subclinical Cushing’s Syndrome in adrenal incidentalomas: a prospective randomized study. Annals of Surgery. 2009;249(3):388-91

  16. Eller-Vainicher C, Morelli V, Salcuni AS, Torlontano M. Postsurgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery? Eur J Endocrinol. 2010;162:91-9

  17. Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endoc Journal. 2011;55:737-45

  18. 18.Iacobone M, Citton M, Viel G, Boetto R, Bonadio I. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal inceidentalomas and subclinical Cushing´s Syndrome. Surgery 2012;152:991-7

  19. 19.Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95(6):2736-45

  20. Van Hulsteijn LT, Pasquali R, Casanueva F, Haluzik M, Ledoux S, Monteiro MP et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. Eur J Endocrinol. 2019;182(1):11-21

  21. Steffensen C, Pereire AM, Dekkers O, Jorgensen J. Diagnosis of endocrine in disease: prevalence of hypercortisolism in type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(6):R256-7

  22. Martínez O. Enfermedades Adrenales. Manual de Prácticas Médicas del Hospital Hermanos Ameijeiras. VI Edición 2018. CEDISAP Ediciones digitales. Publicación en CD. ISBN # 978-959-306-186

  23. Masserini B, Morelli V, Palmieri S, Orsi E, Spada A. Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism. Endoc Journal. 2015;38(6):623-8

  24. Kim B, Chun A, Jung C. Clinical Characteristics and Metabolic Features of Patients with Adrenal Incidentalomas with or without Subclinical Cushing's syndrome. Medline. Seul. 2014;29(4):457-63

  25. Androulakis I, Kaltsas G, Piaditis G, Grossman A. The clinical significance of adrenal incidentalomas. Eur J Clin Invest. 2011;41(5):552-60

  26. Khan, Fatima. Is there an increased risk of cardiovascular disease in patients with funcional adrenal incidentalomas vs. Nonfuncional adrenal incidentalomas Med Journal. 2015;34:15-26

  27. Debono M., Prema A, Hugues B, y Ross J. Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma. J Clin Endocrinol Metab. 2013;98(6):19-71

  28. Tuna M, Nasrolug N, Aycicek B, Becker D. Non- functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. J Endocrinol Invest. 2014;13(8):765-8

  29. Dogruk A, Ayturk S, Aldemir D y Neslihan B. Serum Adiponectin Level as a predictor of Subclinical Cushing´s Syndrome in patients with adrenal incidentaloma. Int J Endocrinol. 2016;(8):19-36

  30. Cho Y, Sunghwan S, Young J, Jeong H, Dongmo J, Hongseok Y Et al. Clinical characteristicsand follow-up in Koe¡rean patients with adrenal incidentalomas. Korean J Intern Med. 2013;28:557-64




2020     |     www.medigraphic.com